f.chowdhury
TL2 Moderator · Konya
Contributes reviews on supplier material. Based in Konya.
Joined 24 September 2025 · last posted 2d · groups: regional-apac
81Posts here
0Topics
2Solutions
1.4kLikes received
1.9kLikes given
20Badges
207Days visited
4.9kPosts read
Recent activity
Full stream-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #100 · Practice › Dosing & titration · 26 Jul 2026 · 27 likes This follows post #97 rather than contradicting it. Micro-titration: the concept of increments smaller than the labelled steps. It has no evidence base from trials but…
-
What the GIP component of tirzepatide is thought to contribute, and how confident we can… Replied, post #16 · Compounds › Tirzepatide · 23 Jul 2026 · 21 likes The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how…
-
Publication patterns in the BPC-157 literature, examined Replied, post #42 · Compounds › Repair & healing peptides · 22 Jul 2026 · 16 likes Worth separating two things that post #38 runs together. TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue protein. The…
-
Common supplements people ask about, assessed one at a time Replied, post #59 · Practice › Interactions · 17 Jul 2026 · 32 likes Thyroid medications: semaglutide is associated with a slowing of gastric emptying, which might affect thyroid medication absorption if they are taken very close…
-
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people… Replied, post #32 · Compounds › Repair & healing peptides · 15 Jul 2026 · 2 likes For anyone arriving from search engines: this subcategory discusses published preclinical work and the absence of published clinical work. It does not endorse or…
-
Journal club: what we got wrong in an earlier session Replied, post #70 · Evidence › Journal club · 10 Jul 2026 · 0 likes On post #66 — agreed on the reasoning, with one qualification. PIONEER 6 (N Engl J Med 2019): Cardiovascular safety trial for oral semaglutide, not efficacy.…
-
Tracking a shortage from primary sources rather than rumour Replied, post #85 · Access › Shortages · 5 Jul 2026 · 2 likes Patient advocacy during shortages: some advocacy groups advocate for patients during shortages. Knowing who they are and following their communication is useful.
-
Journal club: LEADER as the historical anchor Replied, post #99 · Evidence › Journal club · 4 Jul 2026 · 5 likes post #98 is right about the mechanism and I think understates the practical bit. PIONEER 6 (N Engl J Med 2019): Cardiovascular safety trial for oral semaglutide, not…
-
Mass error in ppm: the arithmetic and the caveat — a second dataset Replied, post #16 · Analytics › Mass spectrometry · 4 Jul 2026 · 27 likes Quantitation by MS: most quantitation is done by LC-UV detection at 214 nm, not by MS, because extinction coefficients are better known. MS can quantify if an internal…
-
How to ask a question when you cannot say why you are asking it Replied, post #30 · Start Here › How to Ask · 4 Jul 2026 · 0 likes Asking a follow-up: new topic or reply in the old one? If the answer depends on the previous post, reply. If it is a question that makes sense without the previous…
-
A structured critique template this community uses — a second dataset Replied, post #25 · Evidence › Study critique · 1 Jul 2026 · 7 likes Generalisability: do the inclusion/exclusion criteria narrow the population so much that results do not apply to real people asking about it? This is a fair criticism…
-
Alcohol: what is documented and what is folklore Replied, post #87 · Practice › Interactions · 1 Jul 2026 · 33 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…